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Abstract
 Introduction: The phlebotropic effect of flavonoids is contradictory, and clinically significant effects are poorly 
understood theoretically. The efficiency of flavonoids needs verification by means of the large-scale experimental 
and clinical trials protected from the conflicts of interest.  Research Tasks: Experimental study of venotonic, 
anti-aggregation and endothelioprotectiv properties of the drug Detralex 1000 mg.  Materials and Methods: 
A venotonic effect was investigated after week administration of drug inside on model of the endotelium-
dependent smooth muscle response to increased calcium ion isolated portal vein of rats. The Biopac Bas System 
Station installation including a polygraph of Biopac MP 150 with the TSD-104A module and the software of ACQ 
4.2 was for this purpose used. The protective properties of the endothelium were studied on a 7-day model of 
L-N-nitro-L-arginine-methyl ether-induced rat endothelial dysfunction using invasive blood pressure recording. 
Aggregation of thrombocytes (AT) was investigated by a visual micromethod with use as inductors ADF, a 
collagen, thrombinum, ristomycinum, and adrenaline. Results: In model of endothelial dysfunction rising of 
sensitivity to the contractile response to Сa2+ the isolated segment of a portal vein after use of the drug Detralex 
of 500 mg/kg per day, and also elongation of AT and decrease of coefficient of endothelial dysfunction on a 
background the course reception of the investigated preparation. Conclusion: Pleiotropic effect of micronized 
combination of diosmin and hesperidin, expressed in strengthening the contractile potential of smooth muscle 
veins, improving endothelial function, and lengthening thrombocyte aggregation, was сonfirmed.
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INTRODUCTION
Diseases of the venous system are the most common pathology of peripheral vessels. Venous thromboembolic 
complications are an important cause of death 
and disability in Europe, Russia, and the 
USA. [1] In this regard, import substitution, 
creation of generics, as well as search of 
innovative molecules are an important task 
in world pharmacology. [2,3] At the same 
time, their studying has to be carried out on 
pharmacological targets,[4] in vivo and in vitro 
models.[5] Flavonoids - the most widespread group of the 
drugs which are applied at patients with a disease of peripheric 
veins. It is a group of biologically active substances derivative 
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benzo-g-pirona, the citrus having a natural parentage and 
contained mainly in a peel.[6] In practical medicine, in 
particular, angiology gained the greatest distribution diosmin, 
a hesperidin, rutinum, quercetinum, and their combinations.
Diosmin has the wide range of biological effects which are 
confirmed with numerous researches including renders 
antioxidatic, anti-inflammatory, antimutagen, and antiulcerous 
action.[7] At the same time in a question of effective use of 
drugs of a diosmin, the bioavailability comes to the forefront. 
A number of studies have shown that micronized diosmin 
is superior to the rate of absorption and excretion of non-
micronized analog, which led to improved clinical effect.[8]
There are data, confirmed on the basis of experiments on 
isolated vein segments, on the enhancement of calcium 
ion pressor effects by diosmin.[9] At the same time, the 
hesperidin and its analogs showed vasodilating effect at rats 
with established hypertension. A similar effect was found in 
flavonoid eriodictyol.[10] Follow conclusion about expediency 
of additional researches of flebotonic effect of flavonoids. 
Change of vasoconstrictor activity of the site of a portal 
vein of rats with the switched-off endothelial component 
at introduction of a diosmin in the micronized fraction, 
mediated calcium ion dependent the smooth muscle answer 
and also changes of aggregation properties of thrombocytes 
against the background of N-nitro-L-arginine-methyl ether 
(L-NAME)-model of endothelial dysfunction became a 
subject of our research. The selection of the venous area 
was based on the data on the pacemaker activity of portal 
vein Cajal cells, which allows to track the dynamics of the 
contractile response.[10]
MATERIALS AND METHODS
Experiments are drawn on rat males the Wistar lines. For the 
assessment of calcium ion dependent, the smooth muscle 
answer animals were divided into three groups, on 10 in 
everyone. Group 1 - control (intact rats receiving saline 
in equiobem doses), 2nd group - rats that received the drug 
Detralex 1000 mg in dose of 250 mg/kg, Group 3 - rats 
receiving the drug Detralex in dose of 500 mg/kg. The drug 
was administered 1 time a day for 7 days. For the assessment 
of calcium ion dependent, smooth muscle answer was carried 
out to samples with solutions calcium ion in concentration of 
0.08–1.75 mmol.[9]
A modified Krebs-Henseleit solution was used as the base 
solution, in which the calcium concentration was changed, 
isoosmolarity was achieved by changing the sodium chloride 
content. Oxygenation of solutions was carried out by a 
mixture of gases from 95% O2 and 5% CO2. The drug was 
placed vertically in the tank of the station for testing tissues 
Biopac System Station (initial tension of 0.5 g). The lumen 
of the isolated vein was bandaged up that excluded contact of 
solutions to an endothelium. Registration of contractility of a 
vein was made by means of a polygraph of Biopac MP 150 
with the TSD-104A module and the software of ACQ 4.2.
Endothelial dysfunction was modeled by means of the 
ADMA-similar agent - not selective blocker NO - synthase 
of L-NAME which was entered intraperitoneally in a dose 
of 25 mg/kg/days within 7 days. Hemodynamics indicators: 
Systolic (SBP) arterial blood pressure (ABP), diastolic arterial 
blood pressure (DBP), and heart rate measured continuously 
by means of the sensor and an apparatus complex for invasive 
measurement of indicators of hemodynamics of Biopac (USA) 
and the computer AcqKnowledge 4.2 program. Functional tests: 
Intravenous administration of acetylcholine (40 mg/kg) and 
sodium nitroprusside (30 mg/kg). Development of endothelial 
dysfunction in experimental animals and also extent of its 
correction by the studied drug estimated on the settlement 
coefficient of endothelial dysfunction (CED).[7]
The aggregation of thrombocytes (AT) was investigated by a 
visual micromethod with use as inductors ADF, a collagen, 
thrombinum, ristomycinum, and an adrenaline.
RESULTS AND DISCUSSION
It is established that addition of calcium ion in solution in control 
group led to vein tonus augmentation since concentration of 
0.76 mmol/l, whereas 7-day use of Detralex increased sensitivity of 
a vein to calcium ion with a reliable difference from concentration 
of 0.25 mmol/l. Course introduction of Detralex led to reliable 
augmentation of sensitivity to calcium ion concentration of 0.76 
mmol/l. The effect of drug has dose-dependent character that is 
shown in achievement of the maximum force of reduction at a 
larger dosage of drug in the presence of smaller concentration of 
calcium ion. It is most visually shown in Figure 1.
At introduction of the ADMA-similar agent - L-NAME 
to males within 7 days on the 8th day occurs statistically 
significant rising of SBP and DBP ABP with 135.7 ± 4.1 
and 99.9 ± 3.3 up to 188.3 ± 6.1 and 143.0 ± 2.9 mmHg, 
respectively [Table 1], CED augmentation with 1.2 ± 0.1–5.0 
± 0.6 (P < 0.05), and depression of final metabolites of NO 
with 45.19 ± 2.89–22.69 ± 1.50.
Administering of the studied drug in the studied dose did not 
lead to statistically significant lowering of arterial pressure. 
At the same time, there was dose dependent statistically 
significant reduction of CED.
Introduction non-selective blockers NO synthase causes 
of disturbance of AT that is expressed in its acceleration 
[Table 2]. Administration of the drug Detralex brings in the 
expressed dose-dependent correction of disturbances that 
are shown in elongation of AT. It is established that in the 
maximum therapeutic dose, the greatest the efficiency of 
the drug Detralex is observed when using as the adrenaline 
inductor from 79.4 ± 2.7 to 96.9 ± 3.9 s.
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Results of the made experiment demonstrate dose-dependent 
rising of sensitivity and the contractile response to calcium ion the 
isolated segment of a portal vein at the use of the drug Detralex of 
1000 mg. It demonstrates efficiency of drug even at full dysfunction 
of an endothelium due to influence on calcium ion channels of 
smooth myocytes of a vascular wall, as causes its venotonic action.
[9] Similar increase of calcium ion sensitivity of smooth myocytes 
is defined also under the influence of inhibitors of phosphatase[8] or 
agonists of alpha- adrenoreceptors receptors.[3] In a case with alpha-
adrenoreceptors intensifying of sensitivity most likely is bound to 
G-proteins that mean the accelerated phosphorylation of a myosin 
component of chains.[10] Maintenance of a tonus of vessels happens 
as by means of phosphotazy and kinases; therefore, researches of a 
molecular target of a diosmin from the biochemical point of view 
are expedient.
The obtained data confirm efficiency of the drug Detralex 
of 1000 mg for correction of function of an endothelium and 
restoration of the NO synthesizing function at experimental 
endothelial dysfunction that most likely it is bound to 
augmentation of the activity of antioxidatic enzymes, 
depression of influence of endothelin-1, and a factor of a 
necrosis of a tumor alpha.[5] Elongation of the rate of AT in 
an experiment at group of the animals receiving Detralex is 
caused by decrease of the phenomenon of a stasis, restoration 
of a linear blood flow,[6] and also immediate endotelioprotectiv 
action.
The received results allow to recommend the drug Detralex 
not only as venotonic drug but also as an endotelioprotector 
with antiaggregant properties that are especially important at 
patients with comorbid pathology.
CONCLUSION
Using isolated portal vein of rats model, pleiotropic effect 
of micronized combination of diosmin and hesperidin, 
expressed in strengthening the contractile potential of 
smooth muscle veins, improving endothelial function, and 
lengthening thrombocyte aggregation, was сonfirmed.
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